Welcome to our dedicated page for Establishment Labs Holdings news (Ticker: ESTA), a resource for investors and traders seeking the latest updates and insights on Establishment Labs Holdings stock.
Establishment Labs Holdings Inc. (ESTA) is a leading global medical technology company, renowned for its innovation in the field of medical devices and aesthetics. Specializing in advanced silicone-filled breast and body shaping implants, the company has over 30 years of experience in breast implant manufacturing. Establishment Labs designs, develops, manufactures, and markets an extensive product portfolio that ensures safety and meets the current needs and preferences of plastic surgeons and patients.
Known for its flagship product, Motiva Implants®, Establishment Labs has set a benchmark in the industry for product innovation and safety. The company operates in multiple geographical segments, including Europe, Latin America, Asia-Pacific/Middle East, and other regions. Establishment Labs' products are distributed to medical distributors, physicians, hospitals, and clinics through direct sales channels.
Recent achievements include the continued global expansion of the Motiva Implants® brand and strategic partnerships aimed at advancing medical and aesthetic technology. With a strong focus on the future, the company is dedicated to pushing the boundaries of innovation and safety in medical devices.
Establishment Labs maintains a robust financial condition, driven by its commitment to quality and continuous improvement. The company’s ongoing projects include research and development initiatives aimed at introducing new and improved products that align with market demands.
For the latest updates and relevant information about Establishment Labs Holdings Inc., stay tuned to this page for the most recent news and developments.
Holzer & Holzer, LLC is investigating Establishment Labs Holdings Inc. (NASDAQ:ESTA) for potential compliance failures with federal securities laws. Following a report by Hindenburg Research, which alleged undisclosed conflicts of interest in key safety studies of Establishment Labs' breast implants, the company's stock price experienced a decline. The report claims significant pushback was received by a surgeon for publishing higher complication rates than those reported by the company. Shareholders who incurred losses are encouraged to contact Holzer & Holzer for potential legal recourse.
Establishment Labs Holdings Inc. (NASDAQ: ESTA) will host an investor event on October 5, 2022, at 4:30 p.m. ET, to discuss its innovative product, Mia Femtech®. This minimally invasive procedure aims to enhance breast aesthetics, allowing for a breast size increase of 1 to 2 cups in just 15 minutes, without general anesthesia. The company is pursuing regulatory approvals for Mia in Europe and anticipates commercialization in select markets in the first half of 2023.
Establishment Labs Holdings Inc. (NASDAQ: ESTA), a leader in women's health technology, has secured Hani Zeini for a multiyear advisory role as it prepares for its US market launch. Zeini, with over 30 years in aesthetics, previously founded Sientra. His expertise will drive the company's strategy to introduce innovative breast aesthetics solutions, including the Motiva Implant product suite. With 2.0 million implants distributed globally, Establishment Labs is on track to enhance its market presence.
Establishment Labs Holdings Inc. (Nasdaq: ESTA) reported second-quarter revenues of $41.2 million, a 28.7% increase year-over-year, marking a new record. Adjusted for currency fluctuations, growth would have been 33.3%. Gross profit was 66.7% of revenue, slightly down from 67.1% in 2021. Operating expenses rose to $37.9 million, a 45% increase compared to the previous year. The company maintains its 2022 revenue guidance of $155 million to $165 million. Cash balance stood at $91.3 million as of June 30, 2022, bolstered by a new $225 million credit facility.
Establishment Labs Holdings Inc. (NASDAQ: ESTA) has announced the completion of patient enrollment in the Motiva US IDE clinical study, which involved 827 patients across 32 centers in the US, Germany, and Sweden. The study aims to evaluate the safety and effectiveness of Motiva breast implants in various procedures. The company plans to file its PMA submission to the FDA in Q4 2023, building on this significant milestone, especially amid the challenges posed by the pandemic. The Motiva implants have been positively received in reconstructive surgery.
Establishment Labs Holdings Inc. (NASDAQ: ESTA) will announce its financial results for Q2 2022 on August 8, 2022, after market close. A conference call will be held at 4:30 PM ET to discuss these results. The company specializes in women's health, focusing on breast aesthetics and reconstruction, and has delivered over 2 million Motiva Implants since its launch in 2010. Their implants are known for advanced features that aim to enhance aesthetic and clinical outcomes.
Establishment Labs Holdings Inc. (NASDAQ: ESTA) announced that its CEO, Juan José Chacón-Quirós, and CFO, Raj Denhoy will present at the Jefferies Healthcare Conference on June 8, 2022, at 10:30 am Eastern Time. A live webcast will be available on the company's investor relations website, with an archived version accessible afterward. Founded to enhance women's health, Establishment Labs specializes in breast aesthetics and reconstruction, offering innovative products like Motiva Implants®, with 2 million units distributed globally since 2010.
Establishment Labs Holdings Inc. (NASDAQ: ESTA) reported strong first-quarter 2022 results, with revenue of $38.5 million, a 26.8% year-over-year increase. Despite reaching a record high in sales, gross profit margin declined to 64.8% due to higher inventory reserves. Operating expenses surged 37.5% to $30.5 million, contributing to a net loss of $5.6 million, up from $2.1 million the previous year. The company maintains its revenue guidance of $155 million to $165 million for 2022, reflecting an ambitious growth outlook.
Establishment Labs Holdings Inc. (NASDAQ: ESTA) will announce its financial results for Q1 2022 on May 9, 2022, after market close. A conference call to discuss these results will follow at 4:30 pm ET. Established in 2010, Establishment Labs focuses on improving women’s health, particularly in breast aesthetics and reconstruction, offering Motiva Implants® and related products. More than 2 million Motiva Implants® have been delivered globally. For further details, visit www.establishmentlabs.com.
FAQ
What is the current stock price of Establishment Labs Holdings (ESTA)?
What is the market cap of Establishment Labs Holdings (ESTA)?
What does Establishment Labs Holdings Inc. specialize in?
What is the flagship product of Establishment Labs?
In which regions does Establishment Labs operate?
How does Establishment Labs distribute its products?
What are the recent achievements of Establishment Labs?
What is the focus of Establishment Labs' ongoing projects?
How long has Establishment Labs been in the breast implant manufacturing industry?
What sets Motiva Implants® apart from other products in the market?
Is Establishment Labs a publicly traded company?
Where can I find the latest news about Establishment Labs Holdings Inc.?
